» Articles » PMID: 28826027

CRISPR/Cas9 and PiggyBac-mediated Footprint-free LRRK2-G2019S Knock-in Reveals Neuronal Complexity Phenotypes and α-Synuclein Modulation in Dopaminergic Neurons

Overview
Journal Stem Cell Res
Publisher Elsevier
Specialty Cell Biology
Date 2017 Aug 22
PMID 28826027
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The p.G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) has been identified as the most prevalent genetic cause of familial and sporadic Parkinson's disease (PD). The Cre-LoxP recombination system has been used to correct the LRRK2-G2019S mutation in patient derived human induced pluripotent stem cells (hiPSCs) in order to generate isogenic controls. However, the remaining LoxP site can influence gene expression. In this study, we report the generation of a footprint-free LRRK2-G2019S isogenic hiPS cell line edited with the CRISPR/Cas9 and piggyBac technologies. We observed that the percentage of Tyrosine Hydroxylase (TH) positive neurons with a total neurite length of >2000μm was significantly reduced in LRRK2-G2019S dopaminergic (DA) neurons. The average branch number in LRRK2-G2019S DA neurons was also decreased. In addition, we have shown that in vitro TH positive neurons with a total neurite length of >2000μm were positive for Serine 129 phosphorylated (S129P) alpha-Synuclein (αS) and we hypothesize that S129P-αS plays a role in the maintenance or formation of long neurites. In summary, our footprint-free LRRK2-G2019S isogenic cell lines allow standardized, genetic background independent, in vitro PD modeling and provide new insights into the role of LRRK2-G2019S and S129P-αS in the pathogenesis of PD.

Citing Articles

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.

Bhushan B, Singh K, Kumar S, Bhardwaj A Curr Gene Ther. 2024; 25(1):34-45.

PMID: 38738727 DOI: 10.2174/0115665232292246240426125504.


Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy.

Zhang M, Li H, Jin Y Front Genet. 2024; 15:1364742.

PMID: 38666293 PMC: 11043577. DOI: 10.3389/fgene.2024.1364742.


Micro-and mesoscale aspects of neurodegeneration in engineered human neural networks carrying the LRRK2 G2019S mutation.

Valderhaug V, Ramstad O, van de Wijdeven R, Heiney K, Nichele S, Sandvig A Front Cell Neurosci. 2024; 18:1366098.

PMID: 38644975 PMC: 11026646. DOI: 10.3389/fncel.2024.1366098.


Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing.

Aslan C, Zolbanin N, Faraji F, Jafari R Mol Biotechnol. 2023; 66(11):3092-3116.

PMID: 38012525 DOI: 10.1007/s12033-023-00932-7.


An Update on the Application of CRISPR Technology in Clinical Practice.

Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P Mol Biotechnol. 2023; 66(2):179-197.

PMID: 37269466 PMC: 10239226. DOI: 10.1007/s12033-023-00724-z.